Literature DB >> 20797312

GP130 cytokines and bone remodelling in health and disease.

Natalie A Sims1, Nicole C Walsh.   

Abstract

Cytokines that bind to and signal through the gp130 co-receptor subunit include interleukin (IL)-6, IL-11, oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), and ciliary neutrophic factor (CNTF). Apart from contributing to inflammation, gp130 signalling cytokines also function in the maintenance of bone homeostasis. Expression of each of these cytokines and their ligand-specific receptors is observed in bone and joint cells, and bone-active hormones and inflammatory cytokines regulate their expression. gp130 signalling cytokines have been shown to regulate the differentiation and activity of osteoblasts, osteoclasts and chondrocytes. Furthermore, cytokine and receptor specific gene-knockout mouse models have identified distinct roles for each of these cytokines in regulating bone resorption, bone formation and bone growth. This review will discuss the current models of paracrine and endocrine actions of gp130-signalling cytokines in bone remodelling and growth, as well as their impact in pathologic bone remodelling evident in periodontal disease, rheumatoid arthritis, spondylarthropathies and osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797312     DOI: 10.5483/bmbrep.2010.43.8.513

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  44 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 3.  Coupling factors involved in preserving bone balance.

Authors:  Beom-Jun Kim; Jung-Min Koh
Journal:  Cell Mol Life Sci       Date:  2018-12-04       Impact factor: 9.261

Review 4.  The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity.

Authors:  H Sadie-Van Gijsen; N J Crowther; F S Hough; W F Ferris
Journal:  Cell Mol Life Sci       Date:  2012-11-21       Impact factor: 9.261

5.  Extensive mannose phosphorylation on leukemia inhibitory factor (LIF) controls its extracellular levels by multiple mechanisms.

Authors:  Jarrod Barnes; Jae-Min Lim; Anne Godard; Frédéric Blanchard; Lance Wells; Richard Steet
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

6.  Gomisin N Decreases Inflammatory Cytokine Production in Human Periodontal Ligament Cells.

Authors:  Yoshitaka Hosokawa; Ikuko Hosokawa; Satoru Shindo; Kazumi Ozaki; Takashi Matsuo
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

7.  Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.

Authors:  Celeste Bolin; Ken Tawara; Caleb Sutherland; Jeff Redshaw; Patrick Aranda; Jim Moselhy; Robin Anderson; Cheryl L Jorcyk
Journal:  Genes Cancer       Date:  2012-02

8.  Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.

Authors:  Emma C Walker; Rachelle W Johnson; Yifang Hu; Holly J Brennan; Ingrid J Poulton; Jian-Guo Zhang; Brendan J Jenkins; Gordon K Smyth; Nicos A Nicola; Natalie A Sims
Journal:  J Biol Chem       Date:  2016-08-18       Impact factor: 5.157

Review 9.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

10.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.